Company / EPS (Diluted)
RHYTHM PHARMACEUTICALS, INC. EPS (Diluted) History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$3.20
FY2025
5-year range
-$3.47 / -$1.40
FY2021-FY2025
Trend
+0.0%
vs FY2024
Sector context
#151 of 204
Health Care
What the data says
At $-3.20, RHYTHM PHARMACEUTICALS, INC.'s eps (diluted) ranks #151 of 204 in the Health Care sector. EPS (Diluted) has fluctuated over the past 9 years, ranging from $-3.86 in FY2019 to $-1.18 in FY2017.
Based on SEC 10-K filings.
-3.20 in FY2025.
Declined from $-1.40 to $-3.20 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#151 of 204 in Health CareTop 74% of 204This company -$3.20 Sector average -$0.89
▼
-257.6% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 0.0% year-over-year.
- Ranks #151 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2017.
- Lowest eps (diluted) in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -2.52 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.20 | +0.0% |
| FY2024 | -$3.20 | -128.6% |
| FY2023 | -$1.40 | +59.7% |
| FY2022 | -$3.47 | -147.9% |
| FY2021 | -$1.40 | +53.9% |
| FY2020 | -$3.04 | +21.2% |
| FY2019 | -$3.86 | -35.4% |
| FY2018 | -$2.85 | -141.5% |
| FY2017 | -$1.18 | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026